Investors were still wary of it after the latest earnings release. Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors know ...
Company says it received conditional approval for bird flu vaccine from US Department of Agriculture
Zoetis, the manufacturer behind the vaccine, announced the conditional approval Friday, saying in a news release its scientists had begun updating its existing avian flu vaccine in 2022.
Shares of animal health company Zoetis (NYSE:ZTS) fell 10.6% in the morning session after the company reported disappointing fourth-quarter results: its full-year EPS and revenue guidance fell ...
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing ...
Zoetis, Parsippany, New Jersey, announced Feb. 14 the U.S. Department of Agriculture’s Center for Veterinary Biologics has issued the company a conditional license for its Avian Influenza ...
Zoetis (ZTS) announced that the U.S. Department of Agriculture, Center for Veterinary Biologics, has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed ...
Feb 14 (Reuters) - The U.S. Department of Agriculture has given a conditional approval to Zoetis (ZTS.N), opens new tab to use its bird flu vaccine in poultry, the animal healthcare company said ...
Companion animal product sales grew 8%, while livestock sales declined 3%. These results reflect Zoetis's strong operational capacity, despite facing challenges within the livestock segment.
PARSIPPANY, N.J. (AP) — PARSIPPANY, N.J. (AP) — Zoetis Inc. (ZTS) on Thursday reported fourth-quarter net income of $581 million. The Parsippany, New Jersey-based company said it had net ...
Zoetis is the undisputed leader in the global animal health industry, and we believe it possesses the widest moat of all the competitors. Zoetis has set itself apart based on its impressive ...
Shares of Zoetis (NYSE: ZTS), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up short in its fourth quarter. Zoetis' revenue rose 5% in the quarter to $ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback